Comprehensive Stock Comparison
Compare Syra Health Corp. Class A Common Stock (SYRA) vs Cross Country Healthcare, Inc. (CCRN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | SYRA | 44.7% revenue growth vs CCRN's -33.5% |
| Quality / Margins | CCRN | -1.4% net margin vs SYRA's -16.9% |
| Stability / Safety | CCRN | Beta 0.43 vs SYRA's 0.78, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CCRN | -49.3% vs SYRA's -75.3% |
| Efficiency (ROA) | CCRN | -2.9% ROA vs SYRA's -38.8%, ROIC -3.2% vs -294.7% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Syra Health is a healthcare services company that provides health education, population health management, behavioral health, workforce solutions, and digital health services. It generates revenue through service contracts with government agencies, health networks, and pharmaceutical manufacturers — primarily from its health education and population health management segments. The company's competitive advantage lies in its integrated service portfolio addressing multiple healthcare system pain points, including its Syrenity telehealth platform for mental health services.
Cross Country Healthcare is a healthcare staffing and workforce solutions company that provides temporary and permanent placement of clinical professionals. It generates revenue primarily from nurse and allied staffing services — which account for the majority of its business — along with physician staffing and workforce management solutions. The company's competitive advantage lies in its extensive national network and deep healthcare industry expertise, which enables it to efficiently match qualified professionals with healthcare facilities facing staffing shortages.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CCRN leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). SYRA leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
CCRN is the larger business by revenue, generating $1.1B annually — 150.4x SYRA's $7M. CCRN is the more profitable business, keeping -1.4% of every revenue dollar as net income compared to SYRA's -16.9%. On growth, CCRN holds the edge at -20.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SYRASyra Health Corp.… | CCRNCross Country Hea… |
|---|---|---|
| RevenueTrailing 12 months | $7M | $1.1B |
| EBITDAEarnings before interest/tax | -$1M | $360,000 |
| Net IncomeAfter-tax profit | -$1M | -$16M |
| Free Cash FlowCash after capex | -$231,031 | $46M |
| Gross MarginGross profit ÷ Revenue | +31.4% | +20.2% |
| Operating MarginEBIT ÷ Revenue | -16.9% | -1.4% |
| Net MarginNet income ÷ Revenue | -16.9% | -1.4% |
| FCF MarginFCF ÷ Revenue | -3.1% | +4.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -25.1% | -20.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +67.1% | -2.9% |
Valuation Metrics
| Metric | SYRASyra Health Corp.… | CCRNCross Country Hea… |
|---|---|---|
| Market CapShares × price | $60,000 | $281M |
| Enterprise ValueMkt cap + debt − cash | -$2M | $203M |
| Trailing P/EPrice ÷ TTM EPS | -0.19x | -19.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 106.36x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 319.77x |
| Price / SalesMarket cap ÷ Revenue | 0.01x | 0.21x |
| Price / BookPrice ÷ Book value/share | 0.25x | 0.69x |
| Price / FCFMarket cap ÷ FCF | — | 2.52x |
Profitability & Efficiency
CCRN delivers a -3.8% return on equity — every $100 of shareholder capital generates $-4 in annual profit, vs $-57 for SYRA. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to SYRA's 0.16x. On the Piotroski fundamental quality scale (0–9), CCRN scores 4/9 vs SYRA's 3/9, reflecting mixed financial health.
| Metric | SYRASyra Health Corp.… | CCRNCross Country Hea… |
|---|---|---|
| ROE (TTM)Return on equity | -57.3% | -3.8% |
| ROA (TTM)Return on assets | -38.8% | -2.9% |
| ROICReturn on invested capital | -2.9% | -3.2% |
| ROCEReturn on capital employed | -106.4% | -3.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.16x | 0.01x |
| Net DebtTotal debt minus cash | -$2M | -$78M |
| Cash & Equiv.Liquid assets | $2M | $82M |
| Total DebtShort + long-term debt | $452,077 | $4M |
| Interest CoverageEBIT ÷ Interest expense | -99.37x | -4.55x |
Total Returns (with DRIP)
A $10,000 investment in CCRN five years ago would be worth $7,336 today (with dividends reinvested), compared to $333 for SYRA. Over the past 12 months, CCRN leads with a -49.3% total return vs SYRA's -75.3%. The 3-year compound annual growth rate (CAGR) favors CCRN at -31.0% vs SYRA's -67.8% — a key indicator of consistent wealth creation.
| Metric | SYRASyra Health Corp.… | CCRNCross Country Hea… |
|---|---|---|
| YTD ReturnYear-to-date | +14.9% | +7.9% |
| 1-Year ReturnPast 12 months | -75.3% | -49.3% |
| 3-Year ReturnCumulative with dividends | -96.7% | -67.1% |
| 5-Year ReturnCumulative with dividends | -96.7% | -26.6% |
| 10-Year ReturnCumulative with dividends | -96.7% | -29.9% |
| CAGR (3Y)Annualised 3-year return | -67.8% | -31.0% |
Risk & Volatility
CCRN is the less volatile stock with a 0.43 beta — it tends to amplify market swings less than SYRA's 0.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CCRN currently trades 50.3% from its 52-week high vs SYRA's 24.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SYRASyra Health Corp.… | CCRNCross Country Hea… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.78x | 0.43x |
| 52-Week HighHighest price in past year | $0.41 | $17.30 |
| 52-Week LowLowest price in past year | $0.03 | $7.43 |
| % of 52W HighCurrent price vs 52-week peak | +24.4% | +50.3% |
| RSI (14)Momentum oscillator 0–100 | 51.5 | 53.2 |
| Avg Volume (50D)Average daily shares traded | 12K | 490K |
Analyst Outlook
| Metric | SYRASyra Health Corp.… | CCRNCross Country Hea… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $9.93 |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +13.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Sep 23 | Feb 26 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | 100 | 2.67 | -97.3% |
| Cross Country Healt… (CCRN) | 100 | 36.77 | -63.2% |
Cross Country Healt… (CCRN) returned -27% over 5 years vs Syra Health Corp. C… (SYRA)'s -97%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | $0.00 | $8M | — |
| Cross Country Healt… (CCRN) | $767M | $1.3B | +75.1% |
Cross Country Healthcare, Inc.'s revenue grew from $767M (2015) to $1.3B (2024) — a 6.4% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | -0.2% | -47.1% | -20147.6% |
| Cross Country Healt… (CCRN) | 0.6% | -1.1% | -288.1% |
Cross Country Healthcare, Inc.'s net margin went from 1% (2015) to -1% (2024).
Chart 4P/E Ratio History — 4 Years
| Stock | 2017 | 2023 | Change |
|---|---|---|---|
| Cross Country Healt… (CCRN) | 12.6 | 11 | -12.7% |
Cross Country Healthcare, Inc. has traded in a 5x–13x P/E range over 4 years; current trailing P/E is ~-20x.
Chart 5EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | -0 | -0.52 | -74185.7% |
| Cross Country Healt… (CCRN) | 0.14 | -0.44 | -414.3% |
Cross Country Healthcare, Inc.'s EPS grew from $0.14 (2015) to $-0.44 (2024) — a NaN% CAGR.
Chart 6Free Cash Flow — 5 Years
Syra Health Corp. Class A Common Stock generated $-3M FCF in 2024 (-3015% vs 2021). Cross Country Healthcare, Inc. generated $111M FCF in 2024 (+220% vs 2021).
SYRA vs CCRN: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is SYRA or CCRN a better buy right now?
Analysts rate Cross Country Healthcare, Inc. (CCRN) a "Hold" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SYRA or CCRN?
Over the past 5 years, Cross Country Healthcare, Inc. (CCRN) delivered a total return of -26.6%, compared to -96.7% for Syra Health Corp. Class A Common Stock (SYRA). A $10,000 investment in CCRN five years ago would be worth approximately $7K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CCRN returned -29.9% versus SYRA's -96.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SYRA or CCRN?
By beta (market sensitivity over 5 years), Cross Country Healthcare, Inc. (CCRN) is the lower-risk stock at 0.43β versus Syra Health Corp. Class A Common Stock's 0.78β — meaning SYRA is approximately 83% more volatile than CCRN relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 16% for Syra Health Corp. Class A Common Stock — giving it more financial flexibility in a downturn.
04Which has better profit margins — SYRA or CCRN?
Cross Country Healthcare, Inc. (CCRN) is the more profitable company, earning -1.1% net margin versus -47.1% for Syra Health Corp. Class A Common Stock — meaning it keeps -1.1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCRN leads at -1.3% versus -47.2% for SYRA. At the gross margin level — before operating expenses — SYRA leads at 20.7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — SYRA or CCRN?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is SYRA or CCRN better for a retirement portfolio?
For long-horizon retirement investors, Cross Country Healthcare, Inc. (CCRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.43)). Both have compounded well over 10 years (CCRN: -29.9%, SYRA: -96.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between SYRA and CCRN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.